Uganda - English - National Drug Authority

janssen-cilag international nv - etravirine - oral solid ordinary tablets - 100mg

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

janssen pharmaceutical k.k. - etravirine - white to slightly-yellowish white tablet, major axis 19 mm, minor axis 9.5 mm, thickness 6.6 mm

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - nevirapine anhydrous - tablet, extended release - 400 mg - nevirapine anhydrous 400 mg

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - abacavir as sulfate; dolutegravir as sodium; lamivudine - film coated tablets - dolutegravir as sodium 50 mg; abacavir as sulfate 600 mg; lamivudine 300 mg - lamivudine and abacavir and dolutegravir - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults and adolescents above 12 years of age weighing at least 40 kg.before initiating treatment with abacavir-containing products, screening for carriage of the hla-b*5701 allele should be performed in any hiv-infected patient, irrespective of racial origin. abacavir should not be used in patients known to carry the hla-b*5701 allele.

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - nevirapine - tablet - 200 mg - nevirapine 200 mg

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - tipranavir - hiv infections - antivirals for systemic use - aptivus, co-administered with low-dose ritonavir, is indicated for combination antiretroviral treatment of hiv-1 infection in highly pretreated adults and adolescents 12 years of age or older with virus resistant to multiple protease inhibitors.aptivus should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.this indication is based on the results of two phase-iii studies, performed in highly pretreated adult patients (median number of 12 prior antiretroviral agents) with virus resistant to protease inhibitors and of one phase-ii study investigating pharmacokinetics, safety and efficacy of aptivus in mostly treatment-experienced adolescent patients aged 12 to 18 years.in deciding to initiate treatment with aptivus, co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of aptivus. initiation of treatment should take into account the combinations of mutations which may negatively impact the virological response to aptivus, co-administered with low-dose ritonavir.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - tipranavir - oral solution - 100mg/1ml

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - clarithromycin - granule, for suspension - 250 mg/5 ml - clarithromycin 250 mg/5 ml

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - clarithromycin - granule, for suspension - 125 mg/5 ml - clarithromycin 125 mg/5 ml

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - clarithromycin - tablet, extended release - 500 mg - clarithromycin 500 mg